A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Elayne Chan-Penebre(Epizyme (United States)), Kristy G. Kuplast(Epizyme (United States)), Christina R. Majer, P. Ann Boriack‐Sjodin(Epizyme (United States)), Tim J. Wigle, L. Danielle Johnston(Epizyme (United States)), Nathalie Rioux(Epizyme (United States)), Michael J. Munchhof(Epizyme (United States)), Lei Jin(Agile Therapeutics (United States)), Suzanne L. Jacques(Epizyme (United States)), Kip A. West(Epizyme (United States)), Trupti Lingaraj(Epizyme (United States)), Kimberly Stickland(Epizyme (United States)), Scott Ribich(Epizyme (United States)), Alejandra Raimondi(Epizyme (United States)), Margaret Porter Scott, Nigel J. Waters(Epizyme (United States)), Roy M. Pollock, J. Joshua Smith(Epizyme (United States)), Olena Barbash(GlaxoSmithKline (United States)), Melissa B. Pappalardi(GlaxoSmithKline (United States)), Thau Ho, Kelvin Nurse, Khyati Oza, Kathleen T. Gallagher(GlaxoSmithKline (United States)), Ryan G. Kruger(GlaxoSmithKline (United States)), Mikel P. Moyer, Robert A. Copeland(Epizyme (United States)), Richard Chesworth(Epizyme (United States)), Kenneth W. Duncan(Epizyme (United States))
Cited by 544
Abstract
Related Papers
No related papers found
Powered by citation graph analysis